U.S. patent number 3,652,222 [Application Number 04/814,161] was granted by the patent office on 1972-03-28 for bilirubin assay.
This patent grant is currently assigned to American Monitor Corporation. Invention is credited to Jerry W. Denney, Larry W. Denney.
United States Patent |
3,652,222 |
Denney , et al. |
March 28, 1972 |
**Please see images for:
( Certificate of Correction ) ** |
BILIRUBIN ASSAY
Abstract
The use of an acid solution of hydroxylamine in the analytical
determination of the quantity of direct-reacting and
indirect-reacting bilirubin present in blood serum or body fluids,
to block reaction of bilirubin after a certain stage of the assay
and to prevent interference of substances contained in erythrocytes
in the assay and to stabilize the azobilirubin color formed in the
reaction, and also the use of a form of hydroxylamine in place of
the unstable ascorbic acids used in certain assay procedures.
Inventors: |
Denney; Jerry W. (Indianapolis,
IN), Denney; Larry W. (Indianapolis, IN) |
Assignee: |
American Monitor Corporation
(Indianapolis, IN)
|
Family
ID: |
25214328 |
Appl.
No.: |
04/814,161 |
Filed: |
May 7, 1969 |
Current U.S.
Class: |
436/97;
436/903 |
Current CPC
Class: |
C12Q
1/26 (20130101); Y10S 436/903 (20130101); Y10T
436/146666 (20150115) |
Current International
Class: |
C12Q
1/26 (20060101); G01N 33/72 (20060101); G01n
021/24 (); G01n 031/22 (); G01n 033/16 () |
Field of
Search: |
;23/230,310,253
;252/408 |
References Cited
[Referenced By]
U.S. Patent Documents
Other References
Quigley, J. J., Analytical Chemistry, Vol. 24, pp. 1859-1860 (1952)
.
Welcher, F. J. ed., Standard Methods of Chemical Analysis, Vol. II,
Part A., pp. 1081-1082 (1963).
|
Primary Examiner: Wolk; Morris O.
Assistant Examiner: Katz; Elliott A.
Claims
What is claimed is:
1. In a method for colorimetric or spectrophotometric bilirubin
assay, in which the color of the azobilirubin formed from the
coupling reaction of an azo reagent with bilirubin is measured, the
improvement comprising adding an acid solution of hydroxylamine to
the reactant solution after the azobilirubin has formed
therein.
2. The method as set forth in claim 1, in which the acid solution
of hydroxylamine is prepared by adding hydroxylamine hydrochloride
to water.
3. The method as set forth in claim 1, in which the bilirubin assay
is an alkaline azobilirubin procedure.
4. The method as set forth in claim 1, wherein the hydroxylamine is
added to the reactant solution in place of ascorbic acid.
5. The method as set forth in claim 1, in which the acid
hydroxylamine solution is prepared by dissolving an acid
hydroxylamine salt in water.
6. In a method for colorimetric or spectrophotometric bilirubin
assay, in which the color of azobilirubin formed from the coupling
reaction of an azo reagent with bilirubin is measured, the
improvement comprising using hydroxylamine in the reactant solution
after the azobilirubin has formed therein, the hydroxylamine having
been maintained stable prior to such use by being acidic.
7. The method as set forth in claim 6, in which the bilirubin assay
is an alkaline azobilirubin procedure.
8. The method as set forth in claim 6, wherein the hydroxylamine is
used in place of ascorbic acid.
9. In a method of bilirubin assay involving the measurement of the
blue color of azobilirubin formed by the reaction of bilirubin and
an azo reagent, the improvement comprising using hydroxylamine in a
concentration which gives the same final concentration of
hydroxylamine as when a solution which is 13 molar or greater of
the hydroxylamine is substituted for ascorbic acid in a
Jendrassik-Grof procedure.
Description
I. Introductory Comments as to the Significance, Nature, and Other
Factors as to Bilirubin Present in Blood Serum:
Bilirubin is an orange-colored or yellowish substance or pigment
found and present in blood serum, which is formed from the
hemoglobin of red blood cells and which is formed as a result of
the breakdown of red blood cells normally or as a result of some
bodily condition.
Physiologically it is believed the bilirubin is excreted by the
hepatic or liver cells into the bile. Under normal conditions of
the body, the metabolism of bilirubin is a normal process; and thus
a small amount of bilirubin is usually present in blood serum.
Bilirubin occurs in the blood in two forms, first in the free form
or unconjugated and secondly as bilirubin glucuronide or conjugated
bilirubin. Unconjugated bilirubin is formed as a decomposition
product of erythrocytes and is conjugated and excreted into the
bile by the liver.
The specific determination of the two types of bilirubin yields
diagnostic information which can be used to differentiate various
types of disease states, particularly those relating to jaundice.
For instance, since bilirubin is formed as a result of red cell
destruction or hemolysis, elevated levels of unconjugated bilirubin
are seen in hemolytic states. One of the most common of these is
hemolytic disease of the newborn due to Rh incompatability.
Bilirubin assay is used as an aid in diagnosing this disease but
more importantly is used to follow the course of the disease, since
at a bilirubin level of nearly 20 mg./100 ml. of serum permanent
brain damage can result. To prevent this an exchange blood
transfusion is performed. However, since there is some danger to
the infant's life due to the exchange blood transfusion and since
brain damage is possible, it is particularly necessary that the
physician have an accurate and reliable bilirubin assay upon which
to base his decision.
The amount of each type of bilirubin is also used to differentiate
various types of liver disease. In those liver diseases in which
the liver cells are damaged the cells are unable to conjugate
bilirubin, an unconjugated bilirubin accumulates in the blood. In
those liver diseases characterized by obstructive processes (such
as stones, tumors and other space-occupying lesions) the liver is
unable to excrete bilirubin, and a larger proportion of conjugated
bilirubin appears in the blood.
Conjugated bilirubin is measured as direct reacting bilirubin, and
unconjugated bilirubin is quantitated by measuring total bilirubin
then subtracting direct reacting bilirubin. Thus an accurate direct
reaction assay is necessary both for quantitation of unconjugated
and conjugated bilirubin.
As an example of the importance which has long been placed on
accurate measurement of direct bilirubin Duci.sup.1, Nosslin.sup.2,
and Gambino.sup.3, have independently found that one third of
abnormal bilirubin problems are missed if the direct reaction is
not performed. Moreover, of course it is not possible to
differentiate the type of disease even when the abnormal total
bilirubin level is detected, unless the overall assay yields a
distinction between the direct-reacting as contrasted to
indirect-reacting bilirubin.
Bilirubin assay is also performed on amniotic fluid which surrounds
the fetus in the uterus and is used as an indication of the degree
of erythroblastosis in the fetus. When the assay indicates severe
disease, the infant is delivered prematurely and the disease
process is stopped by exchange transfusion. Of course there is risk
to the child's life by virtue of being prematurely born, and
accurate bilirubin assay is necessary for the physician to make
this decision. Amniotic fluid is a particularly demanding specimen
for this assay since it may contain large amounts of hemolytic
products other than bilirubin which may potentially interfere with
the bilirubin assay.
II. Assaying for Bilirubin: and Disadvantages of Process Using
Ascorbic Acid as A Reagent
The earliest method of quantitating bilirubin involved observing
its yellow color in comparison to yellow standard solutions, by
visual means. This method, although somewhat useful at higher
levels, is only semiquantitative, and thus cannot yield the desired
accuracy which is needed. Furthermore, the visual observation is
rendered less accurate by the fact that there are a number of
yellow pigments in serum, such as carotene, the color of which the
eye cannot separate from the bilirubin pigment; and since this
pigment level varies between 40 and 95 percent of the yellow
pigment in normal serum, the estimate by this means is extremely
crude and unreliable. Moreover, differentiation cannot be made
between conjugated and unconjugated bilirubin by this means.
Spectrophotometric means can be used to measure the yellow pigment,
but since bilirubin itself can absorb at various wave lengths
depending upon other constituents in serum such measurements are
complicated without special equipment.
As long ago as 1883 Ehrlich introduced the diazo reaction for
bilirubin. In this reaction azosulfanilic acid is used to form
azobilirubin. Ehrlich showed that azobilirubin behaves as an
indicator, appearing blue at strongly acid and alkaline pH and red
near neutrality.
Van den Bergh and Muller, other early workers in the field,
demonstrated in 1916 that two types of bilirubin could be
distinguished in serum, a direct reaction which occurs in about 1
minute in the absence of alcohol and an indirect reaction requiring
the addition of alcohol. The former is now known to measure
primarily conjugated bilirubin and the latter both conjugated and
unconjugated bilirubin.
The use of alcohol to cause the reaction of the unconjugated
bilirubin is complicated by the fact that alcohol precipitates
protein; and bilirubin may be coprecipitated with the protein, thus
being subsequently unavailable for the bilirubin measurement in the
supernatant liquid, thus causing a negative error in the
observation. Adler.sup.4,5 as early as 1922, reported that many
substances promote diazo coupling of unconjugated bilirubin and
that many of these are water soluble. In 1937 Malloy and
Evelyn.sup.6 introduced a procedure using methanol in a final
concentration of 50 percent which eliminated protein precipitation;
and although there were many disadvantages such as those due to
spectral shifts, turbidity, and slow reaction, the fact that the
procedure could be used with a standard in chloroform (as opposed
to a difficult-to-prepare standard in serum) caused its widespread
acceptance, and it is used in many if not most of the clinical
laboratories today.
Jendrassik and Grof.sup.7 in 1938 devised a method in which the red
azobilirubin color was formed as in the methods recited above, then
alkali was added transforming the red azobilirubin into the blue
form. The blue color is desirable because there are fewer
interfering pigments in this region. However, in spite of that
desirability, this procedure requires a standard in protein, which
was not then commercially available and which was difficult to
prepare in the laboratory.
Moreover, since unconjugated bilirubin will react even in the
absence of a promoter such as alcohol when in alkaline conditions,
the conversion to alkaline condition complicates the measurement of
conjugated bilirubin. For this reason, ascorbic acid has been added
to the mixture, before alkalinization, to prevent reaction of
unconjugated bilirubin in the direct procedure.
With the development, several years ago, of commercially available
bilirubin standards in serum, the reason for the wide use of the
Malloy-Evelyn method since about 1945 (that is, the usability with
a bilirubin standard in chloroform which could be prepared in the
laboratory) is eliminated. With.sup.8,9 and Fog.sup.10 long ago
recognized the superiority of the Jendrassik Grof method over
others in the literature. Watson.sup.11 commented on the lack of
recognition given the favorable reports of With and Fog, and
suggested that a good method, that is, the method of Jendrassik and
Grof, was not being utilized. The only disadvantage he suggested as
to Jendrassik Grof was a slight sensitivity to hemoglobin.
Moreover, Gambino.sup.12 in the widely circulated "Manual on
Bilirubin Assay" published by the American Society of Clinical
Pathologists, strongly recommended the Jendrassik Grof method over
other methods including that of Malloy and Evelyn, and points out
that the hemoglobin interference of Jendrassik Grof is less than
that of Malloy-Evelyn.
In spite of all these recommendations, the Jendrassik Grof
procedure has not become the most frequently used method in the
clinical laboratory. The reason for this is that the procedure
requires ascorbic acid which is unstable and cannot be used for
even as long as one working day. Accordingly, ascorbic acid, if
prepared for longer than its short stability life, lends to
unreliability of the test; for after becoming unstable, it does not
properly or consistently block the reaction of unconjugated
bilirubin when performing the direct bilirubin procedure, nor
properly or consistently minimize the interference of hemoglobin.
It may perhaps be used by mistake, whether carelessly or
inadvertently or negligently, even after becoming unstable; and the
operator would wrongly interpret the observation. Perhaps the
physician would not know his conclusions were erroneous also. In
fact while control specimens are used for most procedures in the
clinical laboratory, there is no control serum known for direct
reacting bilirubin. At best, the use of ascorbic acid requires the
extra expense of the repetitive small-batch preparation methods
inherently required because of its exceedingly short stability
life; and it has the inherent disadvantage and expense of scrapping
the unused portion of the batch after just a short period of
time.
While the major types of bilirubin assey methods have been
discussed for illustrative purposes, there are a number of what
might be referred to as minor variations of these methods,
differing mainly in the type compound used to promote the reaction
of unconjugated bilirubin with an azo compound and also in the type
azo compound used. After Adler.sup.13 reported in 1922 that many
substances promote diazo coupling of unconjugated bilirubin, a
variety of substances were used, such as urea, caffeine, sodium
benzoate and others.
III. The Present Invention
It has been found that an assay process involving the addition of
an acidic hydroxylamine solution stabilizes the azobilirubin color
after its formation, eliminates interference of hemolysis, and
prevents reaction of unconjugated bilirubin after addition of
alkali. The disadvantageous ascorbic acid is wholly eliminated, and
all its disadvantages are avoided.
While an hydroxylamine compound in just equimolar concentration as
ascorbic acid when substituted for the ascorbic acid used in
bilirubin assay does not achieve the effect of inhibiting
completely the reaction of unconjugated bilirubin after the
addition of alkali in the procedure, it has been found that greatly
increased hydroxylamine concentration, that is, an hydroxylamine
concentration of several times that of the generally used 0.24
molar ascorbic acid, does achieve the desired effect.
Moreover, while both ascorbic acid and hydroxylamine are reducing
agents under some conditions, they are considerably different
compounds, ascorbic acid being an organic compound while
hydroxylamine is an inorganic salt. Moreover, other reducing agents
are either without effect or only partially effective, or, even if
effective in inhibiting the reaction of unconjugated bilirubin,
have other undesirable properties such as developing an interfering
color which might be mistakenly quantitated as bilirubin.
The overall combination of several properties is achieved by the
use of hydroxylamine compounds as herein set forth. That is, the
properties of being compatible with acid conditions in the first
stage of the direct reaction, being effective in the strongly
alkaline pH of the second stage of the reaction, not forming
colored complexes with azo compounds or upon exposure to air during
the test, being stable upon storage in solution, and being
inexpensive to purchase, are unique to hydroxylamine compounds in
solution when stored under acid conditions in a concentration of at
least 1.3 molar when used in the same proportions as would be the
amount of ascorbic acid in the Jendrassik-Grof procedure.
Although hydroxylamine may be advantageously used in bilirubin
assays in conjunction with other promoters and in conjunction with
other azo compounds, the present inventive concepts are set forth
illustratively in what might be referred to as a Jendrassik type
method.
III.A. Reagents
Hydroxylamine Reagent: The hydroxylamine compound used is
hydroxylamine hydrochloride in a 1.6 molar concentration.
Caffeine Reagent: 20 gm. caffeine, 30 gm. sodium benzoate, and 50
gm. sodium acetate are dissolved in 400 ml. of distilled water at
50.degree. to 60.degree. C.
Sulfanilic Acid Reagent: 15 ml. of concentrated HC1 and 5 gm.
sulfanilic acid are added to 500 ml. distilled water, and a
quantity of distilled water sufficient to make 1 liter is
added.
Sodium Nitrite: 100 gm. sodium nitrite is dissolved in 1 liter of
distilled water.
Fehling II Reagent: 100 gm. sodium hydroxide and 350 gm. sodium
potassium tartrate are dissolved in 1 liter distilled water.
Preparation of Diazo Reagent: 20 microliters of the above sodium
nitrite solution is added to 3 ml. of the sulfanilic acid reagent.
The solution is to be used in the following assay procedures within
1 hour after its preparation.
III.B. ASSAY PROCEDURES:
(It will be assumed that the user will have marked two tubes, one
marked "direct" and the other marked "total.")
a. Macro Procedure
1. Add 2.4 ml. 0.05 HC1 to tube marked "direct."
2. Add 2.4 ml. Caffeine Reagent to tube marked "total."
3. Add, and mix with the contents of each tube, 0.3 ml. serum or
plasma.
4. Add, and mix with the contents of each tube, 0.2 ml. Diazo
Reagent. Allow to stand 2 min.
5. Add, and mix with the contents of each tube, 0.1 ml.
Hydroxylamine Hydrochloride Reagent.
6. Add, and mix with the contents of each tube, 1.5 ml. Fehling II
Reagent. Read each tube against a water blank at 600 mu.
b. Micro Procedure
(This procedure is designed for spectrophotometers having a minimum
readout volume of no more than 2 ml., such as the Coleman Jr. using
a 12 .times. 75 mm. cuvette.)
1. Add 1.1 ml. Caffeine Reagent to "total" tube.
2. For a measurement of a direct reacting bilirubin, add 1.1 ml. of
0.05 N HC1 to "direct" tube.
3. To each tube add 0.05 ml. (50 microliters) plasma or serum.
4. Add, and mix with the contents of each tube, 0.1 ml. Diazo
Reagent. Allow to stand 2 minutes.
5. Add, and mix with the contents of each tube, 0.1 ml.
Hydroxylamine Hydrochloride Reagent.
6. Add, and mix with the contents of each tube, 0.7 ml. Fehling II
Reagent. Read against water blank at 600 mu.
An assay according to the novel concepts of the present invention
thus provides multiple advantages: (a) blocking the reaction of
bilirubin after a certain stage of the assay so that it is possible
to distinguish the measurements of conjugated and unconjugated
bilirubin; (b) prevent interference of substances contained in
erythrocytes in the assay, thus, for example, suppressing the
interference of hemolysis of the assay; and (c) stabilizing the
azobilirubin color formed in the reaction, making less critical the
time of the observation. These are all accomplished without the
instability of the ascorbic acid formerly used to achieve those
goals. The ascorbic acid is so unstable that it was not widely
adopted for use in any of the bilirubin assays except the
Jendrassik-Grof procedure, in which it was used in spite of its
instability because the Jendrassik-Grof procedure was not workable
at all in measuring conjugated bilirubin without some means of
blocking the continued reaction of conjugated bilirubin in the
alkaline step.
Accordingly, it will thus be seen from the foregoing description of
the invention according to the embodiments of the invention herein
set forth, that the present invention provides a new and useful
assay yielding quantitative determination of both total and
conjugated bilirubin in serum, plasma, amniotic fluid, or other
biological material to be tested, and provides a method and
reagents therefor, all having desired advantages and
characteristics, and accomplishing the objects of the invention
including the objects and advantages hereinbefore pointed out and
others which are inherent in the invention.
It will be understood that modifications and variations of the
general and specific concepts of the overall assay may be effected
without departing from the novel concepts of this invention;
accordingly, the invention is not to be considered limited to the
specific form or embodiments set forth herein for the purpose of
disclosing and illustrating the inventive concepts discovered and
herein applied.
1. Duci, H. and Watson, C. J., J. Lab. Clin. Med. 30: 293
(1945)
2. Nosslin, B., Scand. J. Clin. Lab. Invest. 12: Supp. 49, 1-176
(1960)
14 Gambino, S.R., Manual on Bilirubin Assay (American Society of
Clinical Pathologists, 1963)
4. Adler, A. and L. Strauss, Klin. Woshschr. 2: 2285 (1922)
5. Adler, A. and L. Strauss, Z. Ges. Exp. Med. 44: 43 (1925)
6. Malloy, H.T. and K.A. Evelyn, J. Biol. Chem. 119: 481 (1937)
7. Jendrassik, L. and P. Grof; Biochem. 2.297: 8 (1938)
8. With, T.K., Acta Physiologica/Scandinavica, 10: 181-192
(1945)
9. With, T.K.; Lancet 618, (1962)
10. Fog. J.; Scand. J. Clin. & Lab. Invest. 10: 241-256
(1958)
11. Watson, D., Clin. Chem. 7: 603-625, (1961)
12. Gambino, S.R., n. 3, supra.
13. Adler, n. 4, supra.
* * * * *